Drug Trial Radar · NCT04445363
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Actual
Start
Aug 12, 2020
Primary completion
Dec 1, 2024
Study completion Dec 1, 2024
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes a dose escalation part(phase I) and a dose extension part(phase II).
Conditions
- Alopecia Areata(AA)
Interventions
Jaktinib hydrochloride creamDrug
Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
PlaceboDrug
Dose extension: Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving 90% Improvement of Severity of Alopecia Tool (SALT90)Time frame: at week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xaingya Hospital,central south university
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.